Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Reduced-Intensity Conditioning (RIC) and Allogeneic Stem Cell Transplantation (allo-SCT) For Relapsed/Refractory Hodgkin Lymphoma (HL) In The Brentuximab Vedotin Era: Favorable Overall and Progression-Free Survival (OS/PFS) With Low Transplant-Related Mortality (TRM)

Paolo Anderlini, MD, Rima M. Saliba, Ph.D., Celina Ledesma, B.S., Christina M Chancoco, Tamera Alexander, P.A., Amin Alousi, MD, Chitra M. Hosing, MD, Issa Khouri, MD, Yago Nieto, M.D., Ph.D., Uday R Popat, MD, Elizabeth J Shpall, MD, Michelle A. Fanale, M.D., Yasuhiro Oki, MD, Jorge E Romaguera, MD, Sattva Neelapu, MD, Anas Younes, M.D., Richard E Champlin, MD

Blood (2013) 122 (21): 410.

https://doi.org/10.1182/blood.V122.21.410.410

Published: 2013

Journal Articles

Durable Responses in Patients Treated with Galiximab (Anti-CD80) in Combination with Rituximab for Relapsed or Refractory Follicular Lymphoma: Long-Term Follow-up of a Phase II Clinical Trial.

Jonathan W. Friedberg, MD, Anas Younes, M.D., David C. Fisher, MD, Leo I. Gordon, MD, Joseph O. Moore, MD, Myron S. Czuczman, MD, Thomas P. Miller, MD, Patrick J. Stiff, MD, Bruce D. Cheson, MD, Andres Forero-Torres, MD, Byron McKinney, M.D., John P. Leonard, MD

Blood (2008) 112 (11): 1004.

https://doi.org/10.1182/blood.V112.11.1004.1004

Published: 2008

Journal Articles

A Phase I Study of Bortezomib in Combination with ICE (BICE) in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma

Michelle A. Fanale, M.D., Luis E. Fayad, M.D., Barbara Pro, M.D., Felipe Samaniego, M.D., Gracy Zachariah, R.N., Cesar A. Nunez, M.D., Yuan Ji, Ph.D., Anas Younes, M.D.

Blood (2008) 112 (11): 3048.

https://doi.org/10.1182/blood.V112.11.3048.3048

Published: 2008

Journal Articles

Pentostatin, Cyclophosphamide, and Rituximab (PCR) Achieve High Response Rates in Indolent B-Cell Lyphoma without Prolonged Myelosuppression

Felipe Samaniego, M.D., Michelle Fanale, M.D., Barbara Pro, M.D., F.B. Hagemeister, M.D., Peter McLaughlin, M.D., Jorge Romaguera, M.D., Sattva Neelapu, M.D., Maria Alma Rodriguez, M.D., Luis Fayad, M.D., Anas Younes, M.D., Larry W. Kwak, M.D., Ph.D

Blood (2008) 112 (11): 835.

https://doi.org/10.1182/blood.V112.11.835.835

Published: 2008

Journal Articles

First-in-Human Phase 1 Dose Escalation Study of NPI-0052, a Novel Proteasome Inhibitor, in Patients with Lymphoma and Solid Tumor

Paul A. Hamlin, MD, Carol Aghajanian, M.D., David Hong, M.D., Anas Younes, M.D., Michael A. Palladino, PhD, Angie M. Longenecker, RN, BSN, Gillian Cropp, MS, G. Kenneth Lloyd, PhD, Alison L. Hannah, MD, Matthew A. Spear, MD, Razelle Kurzrock, MD

Blood (2008) 112 (11): 4939.

https://doi.org/10.1182/blood.V112.11.4939.4939

Published: 2008

Journal Articles

Vorinostat (SAHA) Inhibits STAT6 Phosphorylation and Transcription, Downregulates Bcl-xL, and Induces Apoptosis in Hodgkin Lymphoma (HL) Cell Lines.

Daniela Buglio, MD, Georgios Georgakis, M.D., Kazuhiko Arima, Ph.D., Yong-Jun Liu, Ph.D., Anas Younes, M.D.

Blood (2007) 110 (11): 380.

https://doi.org/10.1182/blood.V110.11.380.380

Published: 2007

Journal Articles

Phase 1 Clinical Trial of a Novel Proteasome Inhibitor (NPI-0052) in Patients with Lymphomas and Solid Tumors.

Razelle Kurzrock, MD, Paul Hamlin, M.D., Anas Younes, M.D., David Hong, M.D., Michael Gordon, M.D., Matthew A. Spear, M.D., Michael A. Palladino, Ph.D., G. Kenneth Lloyd, Ph.D., Angie M. Longenecker, R.N., Saskia T.C. Neuteboom, Ph.D., Gillian F. Cropp, M.S., Alison Hannah, M.D., Carol Aghajanian, M.D.

Blood (2007) 110 (11): 4504.

https://doi.org/10.1182/blood.V110.11.4504.4504

Published: 2007

Journal Articles

Blastoid Mantle Cell Lymphoma (MCL): 5-yr Failure-Free Survival (FFS) Rate of 50%, without Failures after 2.5 Years Following Treatment with Rituximab (R)-HyperCVAD Alternating with R-Methotrexate/Cytarabine (M/A).

Jorge Enrique Romaguera, MD, Luis Fayad, M.D., Maria Alma Rodriguez, M.D., F.B. Hagemeister, M.D., Barbara Pro, M.D., Peter McLaughlin, M.D., Anas Younes, M.D., Felipe Samaniego, M.D., Andre Goy, M.D., Andreas H. Sarris, M.D., Nam H. Dang, M.D., Luhua Wang, M.D., Hagop M. Kantarjian, M.D., Virginia Beasley, L. Jeffrey Medeiros, M.D., Ruth L. Katz, M.D., Fernando Cabanillas, M.D.

Blood (2006) 108 (11): 2749.

https://doi.org/10.1182/blood.V108.11.2749.2749

Published: 2006

Journal Articles

Molecular Mechanisms of the mTOR Inhibitor Temsirolimus (CCI-779) Antiproliferative Effects in Mantle Cell Lymphoma: Induction of Cell Cycle Arrest, Autophagy, and Synergy with Vorinostat (SAHA).

Victor Y. Yazbeck, MD, Georgios V. Georgakis, M.D., Yang Li, M.S., Eiji Iwado, M.D., Seiji Kondo, M.D./PhD, Anas Younes, M.D.

Blood (2006) 108 (11): 2493.

https://doi.org/10.1182/blood.V108.11.2493.2493

Published: 2006

Journal Articles

The mTOR Inhibitor Temsirolimus (CCI-779) Induces Cell Cycle Arrest and Autophagy in Hodgkin Lymphoma (HL) Cell Lines and Enhances the Effect of the PI3-Kinase Inhibitor LY294002.

Georgios V. Georgakis, Victor Y. Yazbeck, Yang Li, Anas Younes, M.D.

Blood (2006) 108 (11): 2259.

https://doi.org/10.1182/blood.V108.11.2259.2259

Published: 2006

Journal Articles

The Histone Deacetylase Inhibitor Vorinostat (SAHA) Induces Apoptosis and Cell Cycle Arrest in Hodgkin Lymphoma (HL) Cell Lines by Altering Several Survival Signaling Pathways and Synergizes with Doxorubicin, Gemcitabine and Bortezomib.

Georgios V. Georgakis, MD, Victor Y. Yazbeck, M.D., Yang Li, M.D., Anas Younes, M.D.

Blood (2006) 108 (11): 2260.

https://doi.org/10.1182/blood.V108.11.2260.2260

Published: 2006

Journal Articles

Sphingosomal Vincristine in CHOP +/− Rituximab Is a Promising New Treatment for Patients with High Risk Untreated Aggressive Non-Hodgkin’s Lymphoma (NHL): Follow-Up Results of a Phase II Study Sphingosomal Vincristine in CHOP +/− Rituximab Is a Promising New Treatment for Patients with High Risk Untreated Aggressive Non-Hodgkin’s Lymphoma (NHL): Follow-Up Results of a Phase II Study.

Maria Alma Rodriguez, M.D., Andreas Sarris, M.D., Nam H. Dang, M.D., Luis Fayad, M.D., Andre Goy, M.D., Fredrick Hagemeister, M.D., Peter McLaughlin, M.D., Barbara Pro, M.D., Jorge Romaguera, M.D., Felipe Samaniego, M.D., Anas Younes, M.D., Fernando Cabanillas, M.D.

Blood (2004) 104 (11): 4602.

https://doi.org/10.1182/blood.V104.11.4602.4602

Published: 2004

Journal Articles

Long-Term Safety and Efficacy of Single Administration of a Fixed Dose Pegfilgrastim (Neulasta) in Inducing Neutrophil Count Recovery after ABVD Chemotherapy in Patients with Hodgkin Lymphoma.

Anas Younes, M.D., Luis Fayad, M.D., Jorge Romaguera, M.D., Barbara Pro, M.D., Andre Goy, M.D., Nam Dang, M.D., Michael Wang, M.D.

Blood (2004) 104 (11): 4646.

https://doi.org/10.1182/blood.V104.11.4646.4646

Published: 2004

Journal Articles

Phase II Study of Oxaliplatin in Patients with Relapsed or Refractory Non-Hodgkin’s Lymphoma: Final Results.

Yasuhiro Oki, M.D., Peter McLauhlin, M.D., Barbara Pro, M.D., Frederick H. Hagemeister, M.D., Archie Bleyer, M.D., Evelyn Loyer, M.D., Anas Younes, M.D.

Blood (2004) 104 (11): 2494.

https://doi.org/10.1182/blood.V104.11.2494.2494

Published: 2004

Journal Articles

A Phase II Study of Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) for Treatment of Patients with Relapsed and Refractory Mantle Cell Lymphoma (MCL).

Yasuhiro Oki, M.D., Barbara Pro, M.D., Ebrahim Delpassand, M. D., Verushka Ballaster, Peter McLaughlin, M.D., Jorge Romaguera, M.D., Michael Wang, M.D., Frederick B. Hagemeister, M.D., Anas Younes, M.D.

Blood (2004) 104 (11): 2632.

https://doi.org/10.1182/blood.V104.11.2632.2632

Published: 2004

Journal Articles

Phase II Study of SGN-30 (Anti-CD30 Monoclonal Antibody) in Patients with Refractory or Recurrent Hodgkin’s Disease.

John P. Leonard, M.D., Joseph D. Rosenblatt, M.D., Nancy L. Bartlett, M.D., Ajay Gopal, M.D., Anas Younes, M.D., David Fisher, M.D., Francine Foss, M.D., Andres Forero, M.D., Steven Bernstein, M.D., Bruce Cheson, M.D., Matthew H. Carabasi, M.D., R. Gregory Bociek, M.D., Bruce Hart, Ph.D., Michael McDonald, M.D.

Blood (2004) 104 (11): 2635.

https://doi.org/10.1182/blood.V104.11.2635.2635

Published: 2004

Journal Articles

Safety and Efficacy of Bortezomib (Velcade) for the Treatment of Relapsed Classical Hodgkin’s Disease.

Anas Younes, M.D., Barbara Pro, M.D., Jorge Romaguera, M.D., Nam Dang, M.D.

Blood (2004) 104 (11): 2638.

https://doi.org/10.1182/blood.V104.11.2638.2638

Published: 2004

Journal Articles

Fc-Gamma Receptor IIIa and Interferon-Gamma SNPs Do Not Predict Responsiveness of Follicular Lymphoma to Galiximab (Anti-CD80 Antibody).

Myron Czuczman, M.D., Bryan R. Leigh, M.D., Thomas E. Witzig, M.D., Julie M. Vose, M.D., Anas Younes, M.D., Baha Alkuzweny, Ph.D., Anne Larocca, Ph.D., Xianjun Cao, M.S., Aron Thall, Ph.D.

Blood (2004) 104 (11): 3292.

https://doi.org/10.1182/blood.V104.11.3292.3292

Published: 2004

NARROW

Reduced-Intensity Conditioning (RIC) and Allogeneic Stem Cell Transplantation (allo-SCT) For Relapsed/Refractory Hodgkin Lymphoma (HL) In The Brentuximab Vedotin Era: Favorable Overall and Progression-Free Survival (OS/PFS) With Low Transplant-Related Mortality (TRM)

Durable Responses in Patients Treated with Galiximab (Anti-CD80) in Combination with Rituximab for Relapsed or Refractory Follicular Lymphoma: Long-Term Follow-up of a Phase II Clinical Trial.

A Phase I Study of Bortezomib in Combination with ICE (BICE) in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma

Pentostatin, Cyclophosphamide, and Rituximab (PCR) Achieve High Response Rates in Indolent B-Cell Lyphoma without Prolonged Myelosuppression

First-in-Human Phase 1 Dose Escalation Study of NPI-0052, a Novel Proteasome Inhibitor, in Patients with Lymphoma and Solid Tumor

Vorinostat (SAHA) Inhibits STAT6 Phosphorylation and Transcription, Downregulates Bcl-xL, and Induces Apoptosis in Hodgkin Lymphoma (HL) Cell Lines.

Phase 1 Clinical Trial of a Novel Proteasome Inhibitor (NPI-0052) in Patients with Lymphomas and Solid Tumors.

Blastoid Mantle Cell Lymphoma (MCL): 5-yr Failure-Free Survival (FFS) Rate of 50%, without Failures after 2.5 Years Following Treatment with Rituximab (R)-HyperCVAD Alternating with R-Methotrexate/Cytarabine (M/A).

Molecular Mechanisms of the mTOR Inhibitor Temsirolimus (CCI-779) Antiproliferative Effects in Mantle Cell Lymphoma: Induction of Cell Cycle Arrest, Autophagy, and Synergy with Vorinostat (SAHA).

The mTOR Inhibitor Temsirolimus (CCI-779) Induces Cell Cycle Arrest and Autophagy in Hodgkin Lymphoma (HL) Cell Lines and Enhances the Effect of the PI3-Kinase Inhibitor LY294002.

The Histone Deacetylase Inhibitor Vorinostat (SAHA) Induces Apoptosis and Cell Cycle Arrest in Hodgkin Lymphoma (HL) Cell Lines by Altering Several Survival Signaling Pathways and Synergizes with Doxorubicin, Gemcitabine and Bortezomib.

Long-Term Safety and Efficacy of Single Administration of a Fixed Dose Pegfilgrastim (Neulasta) in Inducing Neutrophil Count Recovery after ABVD Chemotherapy in Patients with Hodgkin Lymphoma.

Phase II Study of Oxaliplatin in Patients with Relapsed or Refractory Non-Hodgkin’s Lymphoma: Final Results.

A Phase II Study of Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) for Treatment of Patients with Relapsed and Refractory Mantle Cell Lymphoma (MCL).

Phase II Study of SGN-30 (Anti-CD30 Monoclonal Antibody) in Patients with Refractory or Recurrent Hodgkin’s Disease.

Safety and Efficacy of Bortezomib (Velcade) for the Treatment of Relapsed Classical Hodgkin’s Disease.

Fc-Gamma Receptor IIIa and Interferon-Gamma SNPs Do Not Predict Responsiveness of Follicular Lymphoma to Galiximab (Anti-CD80 Antibody).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only